Magnolol-Induced Apoptosis in HCT-116 Colon Cancer Cells Is Associated with the AMP-Activated Protein Kinase Signaling Pathway

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 9, 2012, Pages 1614-1620

  Park, Jun Beom ^a   Lee, Myung Sun ^a   Cha, Eun Young ^a   Lee, Jin Sun ^a   Sul, Ji Young ^a   Song, In Sang ^a   Kim, Ji Yeon ^a  

^a Chungnam National University College of Medicine   (South Korea)

Author keywords

AMP activated protein kinase; Colon cancer; Magnolol

Indexed keywords

CAMPTOTHECIN; CASPASE 3; CYTOCHROME C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAGNOLOL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL INVASION; CELL STRAIN HCT116; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; MIGRATION INHIBITION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84866006480     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00352     Document Type: Article

References (46)

1. Likui W, Hong W, Shuwen Z, Yuangang Y, Yan W. The potential of osteopontin as a therapeutic target for human colorectal cancer. J. Gastrointest. Surg., 15, 652-659 (2011).
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin., 59, 225-249 (2009).
3. Asmis TR, Saltz L. Systemic therapy for colon cancer. Gastroenterol. Clin. North Am., 37, 287-295, ix (2008).
4. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol., 574, 63-71 (2006).
5. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol., 8, 774-785 (2007).
6. Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem. J., 403, 139-148 (2007).
7. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab., 1, 15-25 (2005).
8. Koh H, Chung J. AMPK links energy status to cell structure and mitosis. Biochem. Biophys. Res. Commun., 362, 789-792 (2007).
9. Hwang JT, Ha J, Park IJ, Lee SK, Baik HW, Kim YM, Park OJ. Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett., 247, 115-121 (2007).
10. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol. Oncol., 110, 246-250 (2008).
11. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell, 115, 577-590 (2003).
12. Rattan R, Giri S, Singh AK, Singh I. 5-Aminoimidazole-4-carboxamide-1- beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J. Biol. Chem., 280, 39582-39593 (2005).
13. Su RY, Chao Y, Chen TY, Huang DY, Lin WW. 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNFα-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling. Mol. Cancer Ther., 6, 1562-1571 (2007).
14. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc. Natl. Acad. Sci. U.S.A., 106, 12932-12937 (2009).
15. Khanal P, Oh WK, Thuong PT, Cho SD, Choi HS. 24-Hydroxyursolic acid from the leaves of the Diospyros kaki (Persimmon) induces apoptosis by activation of AMP-activated protein kinase. Planta Med., 76, 689-693 (2010).
16. Kim HJ, Kim SK, Kim BS, Lee SH, Park YS, Park BK, Kim SJ, Kim J, Choi C, Kim JS, Cho SD, Jung JW, Roh KH, Kang KS, Jung JY. Apoptotic effect of quercetin on HT-29 colon cancer cells via the AMPK signaling pathway. J. Agric. Food Chem., 58, 8643-8650 (2010).
17. Yang CS, Wang X. Green tea and cancer prevention. Nutr. Cancer, 62, 931-937 (2010).
18. Lee DH, Szczepanski MJ, Lee YJ. Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J. Cell. Biochem., 106, 1113-1122 (2009).
19. Hwang ES, Park KK. Magnolol suppresses metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in PC-3 human prostate carcinoma cells. Biosci. Biotechnol. Biochem., 74, 961-967 (2010).
20. Chen LC, Liu YC, Liang YC, Ho YS, Lee WS. Magnolol inhibits human glioblastoma cell proliferation through upregulation of p21/Cip1. J. Agric. Food Chem., 57, 7331-7337 (2009).
21. Lin SY, Liu JD, Chang HC, Yeh SD, Lin CH, Lee WS. Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. J. Cell. Biochem., 84, 532-544 (2002).
22. Hsu YF, Lee TS, Lin SY, Hsu SP, Juan SH, Hsu YH, Zhong WB, Lee WS. Involvement of Ras/Raf-1/ERK actions in the magnolol-induced upregulation of p21 and cell-cycle arrest in colon cancer cells. Mol. Carcinog., 46, 275-283 (2007).
23. Jin J, Mullen TD, Hou Q, Bielawski J, Bielawska A, Zhang X, Obeid LM, Hannun YA, Hsu YT. AMPK inhibitor compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells. J. Lipid Res., 50, 2389-2397 (2009).
24. Konoshima T, Kozuka M, Tokuda H, Nishino H, Iwashima A, Haruna M, Ito K, Tanabe M. Studies on inhibitors of skin tumor promotion, IX. Neolignans from Magnolia officinalis. J. Nat. Prod., 54, 816-822 (1991).
25. Zhong WB, Wang CY, Ho KJ, Lu FJ, Chang TC, Lee WS. Magnolol induces apoptosis in human leukemia cells via cytochrome c release and caspase activation. Anticancer Drugs, 14, 211-217 (2003).
26. Lin SY, Chang YT, Liu JD, Yu CH, Ho YS, Lee YH, Lee WS. Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells. Mol. Carcinog., 32, 73-83 (2001).
27. Rasul A, Yu B, Khan M, Zhang K, Iqbal F, Ma T, Yang H. Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways. Int. J. Oncol., 40, 1153-1161 (2012).
28. Chilampalli C, Guillermo R, Zhang X, Kaushik RS, Young A, Zeman D, Hildreth MB, Fahmy H, Dwivedi C. Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action. BMC Cancer, 11, 456-472 (2011).
29. Li HB, Yi X, Gao JM, Ying XX, Guan HQ, Li JC. Magnolol-induced H460 cells death via autophagy but not apoptosis. Arch. Pharm. Res., 30, 1566-1574 (2007).
30. Jin YC, Kim KJ, Kim YM, Ha YM, Kim HJ, Yun UJ, Bae KH, Kim YS, Kang SS, Seo HG, Lee JH, Chang KC. Anti-apoptotic effect of magnolol in myocardial ischemia and reperfusion injury requires extracellular signal-regulated kinase1/2 pathways in rat in vivo. Exp. Biol. Med. (Maywood), 233, 1280-1288 (2008).
31. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology, 144, 5179-5183 (2003).
32. Willer A. Reduction of the individual cancer risk by physical exercise. Onkologie, 26, 283-289 (2003).
33. Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu. Rev. Biochem., 75, 137-163 (2006).
34. Hardie DG. New roles for the LKB1→AMPK pathway. Curr. Opin. Cell Biol., 17, 167-173 (2005).
35. Yu SY, Chan DW, Liu VW, Ngan HY. Inhibition of cervical cancer cell growth through activation of upstream kinases of AMP-activated protein kinase. Tumour Biol., 30, 80-85 (2009).
36. Gusman J, Malonne H, Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis, 22, 1111-1117 (2001).
37. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell, 30, 214-226 (2008).
38. Shaw RJ. Glucose metabolism and cancer. Curr. Opin. Cell Biol., 18, 598-608 (2006).
39. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev., 18, 1926-1945 (2004).
40. Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol. Med., 13, 252-259 (2007).
41. Bourgarel-Rey V, Savry A, Hua G, Carré M, Bressin C, Chacon C, Imbert J, Braguer D, Barra Y. Transcriptional down-regulation of Bcl-2 by vinorelbine: identification of a novel binding site of p53 on Bcl-2 promoter. Biochem. Pharmacol., 78, 1148-1156 (2009).
42. Yuan HD, Quan HY, Zhang Y, Kim SH, Chung SH. 20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon cancer cells is associated with AMPK signaling pathway. Mol. Med. Rep., 3, 825-831 (2010).
43. Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS, Lim JS. Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem. Pharmacol., 83, 385-394 (2012).
44. Sebbagh M, Santoni MJ, Hall B, Borg JP, Schwartz MA. Regulation of LKB1/STRAD localization and function by E-cadherin. Curr. Biol., 19, 37-42 (2009).
45. Kim EK, Park JM, Lim S, Choi JW, Kim HS, Seok H, Seo JK, Oh K, Lee DS, Kim KT, Ryu SH, Suh PG. Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells. J. Biol. Chem., 286, 24036-24045 (2011).
46. Ikeda K, Sakai Y, Nagase H. Inhibitory effect of magnolol on tumour metastasis in mice. Phytother. Res., 17, 933-937 (2003).